Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

123 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
Platzbecker U, Della Porta MG, Santini V, Zeidan AM, Komrokji RS, Shortt J, Valcarcel D, Jonasova A, Dimicoli-Salazar S, Tiong IS, Lin CC, Li J, Zhang J, Giuseppi AC, Kreitz S, Pozharskaya V, Keeperman KL, Rose S, Shetty JK, Hayati S, Vodala S, Prebet T, Degulys A, Paolini S, Cluzeau T, Fenaux P, Garcia-Manero G. Platzbecker U, et al. Among authors: cluzeau t. Lancet. 2023 Jul 29;402(10399):373-385. doi: 10.1016/S0140-6736(23)00874-7. Epub 2023 Jun 10. Lancet. 2023. PMID: 37311468 Clinical Trial.
[We must respect the anti-SARS-CoV-2 vaccine schedule without delay in cancer patients under treatment].
Barrière J, Audigier-Valette C, Borchiellini D, Hoch B, Castelnau O, Francois E, Gastaud L, Skaf R, Berdah JF, Marie W, Lescaut W, Peyrade F, Cluzeau T, Cassuto O, Carles M. Barrière J, et al. Among authors: cluzeau t. Bull Cancer. 2021 Apr;108(4):341-342. doi: 10.1016/j.bulcan.2021.02.003. Epub 2021 Mar 5. Bull Cancer. 2021. PMID: 33741139 Free PMC article. French. No abstract available.
BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice.
Hamouda MA, Jacquel A, Robert G, Puissant A, Richez V, Cassel R, Fenouille N, Roulland S, Gilleron J, Griessinger E, Dubois A, Bailly-Maitre B, Goncalves D, Mallavialle A, Colosetti P, Marchetti S, Amiot M, Gomez-Bougie P, Rochet N, Deckert M, Avet-Loiseau H, Hofman P, Karsenti JM, Jeandel PY, Blin-Wakkach C, Nadel B, Cluzeau T, Anderson KC, Fuzibet JG, Auberger P, Luciano F. Hamouda MA, et al. Among authors: cluzeau t. J Exp Med. 2016 Aug 22;213(9):1705-22. doi: 10.1084/jem.20150983. Epub 2016 Jul 25. J Exp Med. 2016. PMID: 27455953 Free PMC article.
Post-transplantation Burkitt lymphoma: a retrospective study of 55 patients.
Walczak P, Choquet S, Dantal J, Boutboul D, Suarez F, Baron M, Morel V, Cluzeau T, Touati M, Elias M, Bachy E, Nicolas-Virelizier E, Houot R, Venton G, Jacquet C, Moles-Moreau MP, Jardin F, Durot E, Balegroune N, Ecotiere L, Guieze R, Kamar N, Ysebaert L, Couzi L, Gonzalez H, Roulin L, Ou K, Caillard S, Zimmermann H, Trappe RU, Roos-Weil D. Walczak P, et al. Among authors: cluzeau t. Haematologica. 2023 Oct 1;108(10):2814-2819. doi: 10.3324/haematol.2022.282297. Haematologica. 2023. PMID: 36891749 Free PMC article. No abstract available.
Splenectomy before allogeneic hematopoietic cell transplantation for myelofibrosis: A French nationwide study.
Bossard JB, Beuscart JB, Robin M, Mohty M, Barraco F, Chevallier P, Marchand T, Rubio MT, Charbonnier A, Blaise D, Bay JO, Botella-Garcia C, Damaj G, Beckerich F, Ceballos P, Cluzeau T, Cornillon J, Meunier M, Orvain C, Duhamel A, Garnier F, Kiladjian JJ, Yakoub-Agha I; Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC), the France-Intergroupe des Syndromes Myéloprolifératifs (FIM) and the Agence de la BioMédecine (ABM). Bossard JB, et al. Among authors: cluzeau t. Am J Hematol. 2021 Jan;96(1):80-88. doi: 10.1002/ajh.26034. Epub 2020 Nov 18. Am J Hematol. 2021. PMID: 33108024 Free article. Clinical Trial.
LAMP2 expression dictates azacytidine response and prognosis in MDS/AML.
Dubois A, Furstoss N, Calleja A, Zerhouni M, Cluzeau T, Savy C, Marchetti S, Hamouda MA, Boulakirba S, Orange F, Lacas-Gervais S, Karsenti JM, Mounier N, Tamburini J, Puissant A, Luciano F, Jacquel A, Auberger P, Robert G. Dubois A, et al. Among authors: cluzeau t. Leukemia. 2019 Jun;33(6):1501-1513. doi: 10.1038/s41375-018-0336-1. Epub 2019 Jan 3. Leukemia. 2019. PMID: 30607021 Retracted.
Data from French named patient program of quizartinib in relapsed/refractory acute myeloid leukemia.
Fodil S, Raffoux E, Dumas PY, Desbrosses Y, Larosa F, Chantepie S, Larcher MV, Mear JB, Peterlin P, Hunault-Berger M, Hospital MA, Morel V, Lucas N, Vidal V, Salanoubat C, Michel J, Mediavilla C, Ojeda-Uribe M, Alexis M, Frayfer J, Carré M, Maillard N, Redjoul R, Banos A, Detrait M, Cluzeau T, Wickenhauser S, Chaoui D, Elassy M, Pigneux A, Dombret H, Récher C, Bertoli S; French AML Intergroup ALFA/FILO. Fodil S, et al. Among authors: cluzeau t. Leuk Lymphoma. 2021 Jul;62(7):1756-1760. doi: 10.1080/10428194.2021.1881505. Epub 2021 Feb 17. Leuk Lymphoma. 2021. PMID: 33596765 No abstract available.
123 results